Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | GBA1 | P04062 | 6/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312474 | 0.90 | HRH4 (0.49) | CYP19A1HRH4HRH3GBA1L3MBTL1 | |
| SCHEMBL9926327 | 0.90 | CYP19A1 (0.49) | CYP19A1ADRB2HRH4HRH3GBA1 | |
| SCHEMBL3434880 | 0.89 | DDX3X (0.39) | CYP19A1ADRB2HRH4HRH3GBA1 | |
| SCHEMBL10299507 | 0.89 | HRH4 (0.54) | CYP19A1HRH4HRH3GBA1 | |
| SCHEMBL5021126 | 0.89 | CYP19A1 (0.48) | CYP19A1ADRB2HRH4HRH3GBA1 | |
| SCHEMBL18757279 | 0.87 | CYP19A1 (0.56) | CYP19A1HRH4HRH3GBA1 | |
| SCHEMBL10079147 | 0.87 | CYP19A1 (0.56) | CYP19A1HRH4HRH3GBA1 | |
| SCHEMBL12641729 | 0.87 | GBA1 (0.49) | CYP19A1ADRB2HRH4HRH3GBA1 | |
| SCHEMBL19224588 | 0.87 | CYP19A1 (0.56) | CYP19A1HRH4HRH3GBA1 | |
| SCHEMBL3542321 | 0.87 | GBA1 (0.49) | CYP19A1ADRB2HRH4HRH3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapetics Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | CYP19A1 1614/4885ADRB2 3210/4885HRH4 1851/4885 |
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | RAB5IF, RPS27A, PSMA6 | CYP19A1 3822/4885ADRB2 4843/4885HRH4 4826/4885 |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | CYP19A1 2366/4885ADRB2 4368/4885HRH4 1806/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | CYP19A1 1614/4885ADRB2 3210/4885HRH4 1851/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | CYP19A1 3250/4885ADRB2 4673/4885HRH4 4246/4885 |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | CYP19A1 3811/4885ADRB2 4850/4885HRH4 4334/4885 |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | CYP19A1 1614/4885ADRB2 3210/4885HRH4 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.